The stock of Lifecore Biomedical Inc. (NASDAQ:LFCR) last traded at $6.64, up 4.57% from the previous session.
Data from the available sources indicates that Lifecore Biomedical Inc. (NASDAQ:LFCR) is covered by 4 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $16.00 and a low of $11.00, we find $13.00. Given the previous closing price of $6.35, this indicates a potential upside of 104.72 percent. LFCR stock price is now -16.98% away from the 50-day moving average and -29.47% away from the 200-day moving average. The market capitalization of the company currently stands at $194.55M.
In total, 0 analysts have assigned it a hold rating, and 4 have given it a buy rating. Brokers who have rated the stock have averaged $13.25 as their price target over the next twelve months.
Insiders disposed of 30,329 shares of company stock worth roughly $0.2 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LFCR stock. A new stake in Lifecore Biomedical Inc. shares was purchased by GSA CAPITAL PARTNERS LLP during the first quarter worth $102,000. MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. invested $72,000 in shares of LFCR during the first quarter. In the first quarter, AMALGAMATED FINANCIAL CORP. acquired a new stake in Lifecore Biomedical Inc. valued at approximately $21,000. AQUATIC CAPITAL MANAGEMENT LLC acquired a new stake in LFCR for approximately $16,000.
With an opening price of $6.23 on Tuesday morning, Lifecore Biomedical Inc. (NASDAQ: LFCR) set off the trading day. During the past 12 months, Lifecore Biomedical Inc. has had a low of $5.94 and a high of $12.04. As of last week, the company has a debt-to-equity ratio of 1.47, a current ratio of 1.40, and a quick ratio of 0.60. The fifty day moving average price for LFCR is $7.95 and a two-hundred day moving average price translates $9.39 for the stock.
The company reported revenue of $43.35 million for the quarter, compared to $41.63 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.14 percent.